Across the globe, the pharma supply chain has been under attack from governments, regulators and other key stakeholders for many a year. Issues such as high costs, slow response times, poor quality levels, economic adulteration of materials, shortages, consent decrees, counterfeiting, product diversion and theft consistently rear their ugly heads.
Stakeholders have been moved to try and stem the tide, with legislation passed on either side of the pond calling for safety measures to be applied and all manner of expensive technology adopted to mitigate some of the damage.
But wait, what are those developing and selling medicines doing to play their part, aside from following the dictate of governments and regulators?
See pdf of full article here: mc-n-strategic-design-supply-chain